The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients

Arthritis Research and Therapy

Volumn 14, Issue 2, 2012, Pages

  Raterman, Hennie G ^a   Vosslamber, Saskia ^a   de Ridder, Sander ^a   Nurmohamed, Michael T ^b   Lems, Willem F ^a,b   Boers, Maarten ^a,b   van de Wiel, Mark ^a   Dijkmans, Ben A C ^a,b   Verweij, Cornelis L ^a   Voskuyl, Alexandre E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Jan Van Breemen Research Institute/Reade   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLEMASTINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; METHYLPREDNISOLONE; MYXOVIRUS RESISTANCE PROTEIN A; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREDNISOLONE; RITUXIMAB; RNA; MONOCLONAL ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD CELL; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; DRUG RESPONSE; EPSTI1 GENE; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ASSOCIATION; HERC5 GENE; HUMAN; HUMAN TISSUE; IFI44L GENE; IMMUNE RESPONSE GENE; ISG15 GENE; LY6E GENE; MALE; MICROARRAY ANALYSIS; MXB GENE; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; RSAD2 GENE; AGED; DRUG EFFECT; FOLLOW UP; GENE REGULATORY NETWORK; GENETICS; METHODOLOGY; MIDDLE AGED; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; GENE REGULATORY NETWORKS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTERFERON TYPE I; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84860215051     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3819     Document Type: Article

References (39)

1. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50:380-386. 10.1002/art.20018, 14872479.
2. Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48:2741-2749. 10.1002/art.11223, 14558078.
3. Roosnek E, Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med 1991, 173:487-489. 10.1084/jem.173.2.487, 2118796, 1703209.
4. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, Holers VM. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006, 116:961-973. 10.1172/JCI25422, 1421345, 16585962.
5. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002, 297:1689-1692. 10.1126/science.1073176, 12215644.
6. Marston B, Palanichamy A, Anolik JH. B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr Opin Rheumatol 2010, 22:307-315. 10.1097/BOR.0b013e3283369cb8, 2947313, 20090526.
7. Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am 2004, 30:393-403. viii, 10.1016/j.rdc.2004.01.006, 15172048.
8. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806. 10.1002/art.22025, 16947627.
9. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006, 54:1390-1400. 10.1002/art.21778, 16649186.
10. Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, Cimmino M, Morassi P, Masolini P, Pellerito R, Cutolo M, Puttini PS, De Vita S. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 2009, 48:1557-1559.
11. Finckh A, Ciurea A, Brulhart L, Moller B, Walker UA, Courvoisier D, Kyburz D, Dudler J, Gabay C. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?. Ann Rheum Dis 2010, 69:387-393. 10.1136/ard.2008.105064, 2800201, 19416802.
12. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008, 58:2993-2999. 10.1002/art.23902, 18821683.
13. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011, 70:1575-1580. 10.1136/ard.2010.148759, 21571731.
14. Fabris M, Quartuccio L, Lombardi S, Saracco M, Atzeni F, Carletto A, Cimmino M, Fabro C, Pontarini E, Pellerito R, Bambara LM, Sarzi-Puttini P, Cutolo M, Manfredi M, Benucci M, Morassi P, Fischetti F, Padovan M, Govoni M, Curcio F, Tonutti E, De Vita S. The CC homozygosis of the -174G > C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun Rev 2012, 11:315-320. 10.1016/j.autrev.2010.06.012, 20974296.
15. Magnusson M, Brisslert M, Zendjanchi K, Lindh M, Bokarewa MI. Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment. Rheumatology (Oxford) 2010, 49:1911-1919.
16. Julia A, Barcelo M, Erra A, Palacio C, Marsal S. Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells. Pharmacogenomics 2009, 10:1697-1708. 10.2217/pgs.09.99, 19842941.
17. Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing DM, van Baarsen LG, Bos C, Kirou KA, Gerlag DM, Crow MK, Bijlsma JW, Verweij CL, Tak PP. The relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis. Arthritis Rheum 2010, 62:3607-3614. 10.1002/art.27702, 20722020.
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
19. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107, 7818570.
20. van Gestel AM, Prevoo MLL, van't Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PLCM. Development and validation of the European League against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League against Rheumatism criteria. Arthritis Rheum 1996, 39:34-40. 10.1002/art.1780390105, 8546736.
21. Vosslamber S, Raterman HG, Pouw Kraan T, Schreurs M, Blomberg von M, Nurmohamed MT, Lems WF, Dijkmans BA, Voskuyl A, Verweij C. Pharmacological induction of IFN type I activity following therapy with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis 2011, 70:1153-1159. 10.1136/ard.2010.147199, 21444302.
22. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193. 10.1093/bioinformatics/19.2.185, 12538238.
23. Rainer J, Sanchez-Cabo F, Stocker G, Sturn A, Trajanoski Z. CARMAweb: comprehensive R- and bioconductor-based web service for microarray data analysis. Nucleic Acids Res 2006, 34:W498-W503. 10.1093/nar/gkl038, 1538903, 16845058.
24. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868. 10.1073/pnas.95.25.14863, 24541, 9843981.
25. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116-5121. 10.1073/pnas.091062498, 33173, 11309499.
26. Eisen Software. , http://rana.lbl.gov/EisenSoftware.htm
27. Ingenuity. , http://www.ingenuity.com/products/pathways_analysis.html
28. Team RDC. R: A language and Environment for Statistical Computing. 2008, Vienne Austria: R Foundation for Statistical Computing.
29. Vince Carey and Henning Redestig for C++ language enhancements ROC: utilities for ROC, with uarray focus R package version 1.26.0, Vince Carey and Henning Redestig for C++ language enhancements.
30. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581. 10.1056/NEJMoa032534, 15201414.
31. Interpreting Diagnostic Tests. , http://gim.unmc.edu/dxtests/Default.htm
32. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, Ibrahim SM, Fero M, Dijkmans BA, Tak PP, Verweij CL. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007, 66:1008-1014. 10.1136/ard.2006.063412, 1954704, 17223656.
33. Mavragani CP, La DT, Stohl W, Crow MK. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum 2010, 62:392-401. 10.1002/art.27226, 2821991, 20112385.
34. Higgs BW, Liu Z, White B, Morehouse C, Brohawn P, Kiener PA, Richman L, Fiorentino D, Greenberg SA, Jallal B, Yao Y. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011, 70:2029-2036. 10.1136/ard.2011.150326, 21803750.
35. O'Hanlon TP, Rider LG, Gan L, Fannin R, Paules RS, Umbach DM, Weinberg CR, Shah RR, Mav D, Gourley MF, Miller FW. Gene expression profiles from discordant monozygotic twins suggest that molecular pathways are shared among multiple systemic autoimmune diseases. Arthritis Res Ther 2011, 13:R69. 10.1186/ar3330, 3132064, 21521520.
36. Cantaert T, van Baarsen LG, Wijbrandts CA, Thurlings RM, van de Sande MG, Bos C, van der Pouw TK, Verweij CL, Tak PP, Baeten DL. Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. Rheumatology (Oxford) 2010, 49:156-166.
37. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006, 54:723-732. 10.1002/art.21650, 16508933.
38. Jego G, Pascual V, Palucka AK, Banchereau J. Dendritic cells control B cell growth and differentiation. Curr Dir Autoimmun 2005, 8:124-139.
39. Toubi E, Kessel A, Slobodin G, Boulman N, Pavlotzky E, Zisman D, Rozenbaum M, Rosner I. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66:818-820. 10.1136/ard.2006.062505, 1954671, 17148544.